Landos Biopharma, Inc. (LABP) Tops Q4 EPS by 6c

Landos Biopharma, Inc. (NASDAQ: LABP) reported Q4 EPS of ($0.13), $0.06 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Landos Biopharma, Inc. (LABP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49